强化降压未降低 2 型糖尿病成人痴呆或轻度认知障碍发生率,但减缓脑白质病变体积增长(BPROAD 试验预设次要结局分析)
Effect of intensive blood pressure control on cognitive outcomes and brain structures in adults with type 2 diabetes: prespecified analysis of secondary outcomes of BPROAD randomised controlled trial
BPROAD 随机对照试验的预设次要结局分析显示,2 型糖尿病成人将收缩压强化降至 <120 mm Hg 与标准降至 <140 mm Hg 相比,未降低痴呆或轻度认知障碍复合结局发生率(HR 0.96,95% CI 0.86–1.06;P=0.38)。
- 背景
- BPROAD 是一项以收缩压目标为核心变量的降压随机试验:强化治疗瞄准 <120 mmHg,标准治疗瞄准 <140 mmHg。此次报告的是该试验预设的次要结局分析,把评价范围从心血管事件扩展到认知功能与脑结构。它要回答两个问题:把收缩压降到更低水平,能否减少全因痴呆与轻度认知损害的发生;以及能否改变脑白质病变体积、全脑总体积这类影像学指标。研究对象限定在 ≥50 岁、2 型糖尿病、收缩压升高且心血管风险增加的成人。
- 做法
- 多中心、开放标签、结局评估者盲法的随机对照试验,在中国七个地理区域的 145 家临床中心开展。12 821 名 ≥50 岁、患 2 型糖尿病、收缩压升高且心血管风险增加的成人入组,其中基线无可能痴呆的 12 434 人进入认知辅助研究。随机分为强化组 6219 人与标准组 6215 人,分别以收缩压 <120 mmHg 和 <140 mmHg 为目标,干预最长五年。认知评估在每年及研究结束时进行。主要认知结局是全因痴呆或轻度认知损害的复合终点;次要结局包括全因痴呆、轻度认知损害、认知功能变化及脑 MRI 特征变化。影像部分为子研究:基线 862 人、研究结束时 605 人接受脑 MRI,用于测量白质病变体积与全脑总体积的变化。基线平均年龄 63.7 岁,女性 5567 人(44.8%)。治疗一年后,强化组平均收缩压 121.6 mmHg,标准组 133.2 mmHg。
- 结论
- 中位随访 3.8 年内,主要复合终点在强化组发生 747 例(3.69/100 人年),标准组 783 例(3.89/100 人年),风险比 0.96(95% 置信区间 0.86 至 1.06),P=0.38,两组差异无统计学意义。脑 MRI 子研究纳入强化组 428 人、标准组 434 人,强化组的白质病变体积增幅小于标准组,组间差值为 −0.09(反双曲正弦变换后的 cm³),95% 置信区间 −0.15 至 −0.02,P=0.01。摘要给出的结论是:在中位约四年的观察期内,两个血压目标之间未观察到全因痴呆或轻度认知损害复合终点的显著差异,而强化治疗与脑白质病变体积累积减少相关。
- 意义
- 这批数据把「更低血压是否护脑」的问题放进一个上万人、多中心、预设结局的框架里检验:在痴呆与轻度认知损害这一硬认知终点上两组没有分出高下,而在白质病变体积这一影像学终点上出现了方向明确的差异。对需要权衡强化降压净获益的读者,两个终点上的不同结果本身就是可用信息。
- 局限
- 脑 MRI 只在部分参与者中完成,基线 862 人、研究结束时 605 人,影像结论来自这一子集;认知结局的观察窗口为中位 3.8 年、干预最长五年,报告的是这一时间范围内的结果。
原文摘要
出版方登记 · CrossrefObjective To evaluate the effect of intensive compared with standard treatment of systolic blood pressure (SBP) on cognitive outcomes and brain structures in adults with type 2 diabetes. Design Multicentre, open label, outcome assessor masked, randomised controlled trial. Setting 145 clinical centres across seven geographical regions in China. Participants 12 821 adults aged ≥50 years with type 2 diabetes, raised SBP, and increased cardiovascular risk, of whom 12 434 without probable dementia at baseline were included in this cognitive ancillary study. Further assessments were performed annually and at the end of study. Interventions Participants were randomly assigned to receive intensive treatment targeting SBP <120 mm Hg or standard treatment targeting SBP <140 mm Hg for up to five years. Main outcome measures The primary cognitive outcome was a composite of all cause dementia or mild cognitive impairment. Secondary cognitive outcomes included all cause dementia, mild cognitive impairment, changes in cognitive functions, and changes in brain magnetic resonance imaging (MRI) characteristics. A subset of participants underwent brain MRI at baseline (n=862) and at the end of study (n=605) to assess changes in white matter lesion volume and total brain volume. Results 6219 participants were assigned to receive intensive treatment and 6215 to receive standard treatment. Baseline mean age was 63.7 years, and 5567 (44.8%) participants were women. After one year, mean SBP was 121.6 mm Hg in the intensive treatment group and 133.2 mm Hg in the standard treatment group. During a median follow-up of 3.8 years, the primary cognitive outcome of all cause dementia or mild cognitive impairment occurred in 747 participants (3.69 events per 100 person years) in the intensive treatment group and 783 participants (3.89 events per 100 person years) in the standard treatment group (hazard ratio 0.96, 95% confidence interval (CI) 0.86 to 1.06; P=0.38). In the MRI substudy (428 intensive treatment v 434 standard treatment), the intensive treatment group had a smaller increase in white matter lesion volume compared with the standard treatment group (between group difference −0.09 inverse hyperbolic sine (asinh) transformed cm 3 , 95% CI −0.15 to −0.02; P=0.01). Conclusions Over a median of about four years, no statistically significant difference in incidence of a composite of all cause dementia or mild cognitive impairment was observed among adults with type 2 diabetes receiving standard treatment of SBP (target <140 mm Hg) and intensive treatment (target <120 mm Hg). Intensive treatment was, however, associated with a reduction in the accrual of cerebral white matter lesion volume. Trial registration ClinicalTrials.gov NCT03808311 .
页面未能读取全文,以上为出版方登记的摘要;方法与图表见原文
本页是 AI 精读,不转载论文原文;完整论文(含方法、图表与参考文献)见原文
来源:BMJ · doi.org